Member Info for dickie3times

Posting scurrilous claims aforethought.

If it happens it happens...just don't help it down.
I am watching this p...k with a view to getting him suspended.

Australia is on the verge of another total lockdown . The latedt spread of the bery fast spreading Delta strain began in Sydney through a taxi drivre infecting dozens of passengers to and from the airport. This time they could be more drastic. But how it will affect mining is to be seen.

Lines on the Antiquity of Microbes", also known simply as "Fleas", is a couplet commonly cited as the shortest poem ever written, composed by American poet Strickland Gillilan in the early 20th century.

The poem reads in full:

Adam
Had 'em.

Short poem by Bogden Bash entitled...
And something about fleas...

ADAM HAD"EM

No panic.....though now i am underwater.
I am NOT going to say " we need news..."

No worry no cry...

...
....

Barberdhop...thanks for the article...nice encouraging read ...

https://total-market-solutions.com/2021/07/hemogenyx-pharmaceuticals-3/

Much in the pipeline and negotiations with ‘famous’ names are ongoing for Hemogenyx Pharmaceuticals


“We’re about making drugs to treat patients, save lives and everything else will follow…including the share price”


The summer heat is intense, the markets celebrated ‘Freedom Day’ with a meltdown, but while traders are hot and bothered, the scientists at Hemogenyx Pharmaceuticals are cooly and cheerfully making progress with their clinical candidates, and doing so at speed.

However, the company will not be rushed into making announcements until their findings, of which there are several, are “bullet proof” in terms of being protected, repeatable and reproducible.

Founder and chief executive Dr Vladimir Sandler says the main thrust of the company is concentrating on what it can achieve in terms of moving its product candidates into clinical trials. “Without it we can not move to the next stage.”

“Our goal is to go into and to open an IND (investigational new drug), and go into clinical trials with at least one product candidate, and at this point the most realistic product candidate that will probably go into clinical trials will be CART T. That’s where our attention is, and this is what we’re doing every day 24/7.”

Hemogenyx has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia. CAR-T therapy is a treatment in which a patient’s own T cells, a type of immune cell, are modified to recognise and kill the patient’s cancer cells.

Whilst progress with CART T may define the company in the short term, as Vlad explains to Sarah Lowther there is much in the pipeline and negotiations with ‘famous’ names are ongoing.

Stonk....great maths. What would we do without you. Lol

I imagine many athleted are feeling dejected. Hoe can they possibly build the intensity of competition with no crowds and the thought of staying in there rooms not being allowef in bars or shops or restaurants. If i was there i would not want to compete and if i did it would be half hearted.

Iceman...agree, stocks everywhere are down. Negative vibes out of Japan over covid in Olympic village could be spooking the markets. If it gets worse, there will be pressure to cancel/delay yet again which may impact the Yen and in turn Wall St.
OMO

Only My Opinion

Not heard a dicky bird.....tweet tweet tweet

Jezconnor.....Hopefully although is an RNS not meant to be released as soon as practically possible? If so any news would have been released by now, unless something is being signed today

True...but i believe RNS is not yet ready for release. Hence delay the interview so both can be released together

(Extract continued)

A new Polish wholly owned subsidiary of Mkango, Mkango Polska, has been established and a highly experienced Country Director for Poland, Dr Jaroslaw Paczek, has been appointed, together with rare earth separation experts, Carester, and a strong team of technical advisors and engineers.

https://www.investegate.co.uk/mkango-resources-ltd--mka-/rns/mkango-to-create-rare-earths-hub-in-poland/202106070700109361A/

Grupa Azoty PULAWY (Warsaw Stock Exchange: ZAP) is part of The Grupa Azoty Group, the European Union's second largest manufacturer of nitrogen and compound fertilizers, and a major chemicals producer. Its products are exported to over 20 countries around the world, including Europe, the Americas and Asia.

The Parties have signed an exclusive lease option agreement for a site adjacent to Grupa Azoty PULAWY's large scale fertiliser and chemicals complex at Pulawy in Poland, which provides excellent infrastructure, access to reagents and utilities on site, and an attractive operating environment, resulting in a highly competitive operating cost position for the Plant, based on scoping studies to date.

Located within a Polish Special Economic Zone, the site provides excellent access to European and international markets. Production from the Plant will strengthen Europe's security of supply for rare earths, used in electric vehicles, wind turbines and other green technology and strategic applications, and aligns with European initiatives to create more robust, diversified supply chains.

Development of the Plant is expected to bring significant benefits to the Mkango group:

o Higher value-added products with increased margins - targeting 2,000 tonnes per year of separated neodymium (Nd) / praseodymium (Pr) oxides, and 50 tonnes per year dysprosium (Dy) and terbium (Tb) oxides in a heavy rare earth enriched carbonate

o Greater integration - plant development fully underpinned by sustainably sourced, purified mixed rare earth carbonate from Mkango's Songwe Hill operations, with other synergies being evaluated

o Increased marketing flexibility with a broader range of potential customers - future opportunities to produce and market separated heavy rare earths

o Catalyst for regional growth and the green transition - potential for further downstream developments and related businesses, including renewables, creating additional jobs in the region

Engagement with financial institutions is underway to accelerate development, and additional strategic partnerships, downstream developments and marketing opportunities are being evaluated.

Feasibility studies for the Plant are being undertaken in parallel with Mkango's Songwe Hill rare earths project ("Songwe") in Malawi and other opportunities, including Mkango's interest in HyProMag Limited, which is developing production of short loop recycled rare earth magnets in the UK.

(Extract continued)

https://www.investegate.co.uk/mkango-resources-ltd--mka-/rns/mkango-to-create-rare-earths-hub-in-poland/202106070700109361A/

We are looking forward to working with Mkango and Grupa Azoty PULAWY on this groundbreaking project for Poland and Europe. "

Pulawy Rare Earths Separation Plant

The Plant is expected to initially produce approximately 2,000 tonnes per year of neodymium, praseodymium and / or didymium (NdPr) oxides as well as a heavy rare earth enriched carbonate, containing approximately 50 tonnes per year dysprosium and terbium oxides. It is also expected to produce lanthanum cerium carbonate. Mkango is evaluating marketing and processing options for the heavy rare earth enriched carbonate and lanthanum cerium carbonate. The Plant will use best-in-class, conventional and proven technology, and will benefit from excellent rail and road infrastructure as well as the direct supply of the required processing reagents from Grupa Azoty PULAWY. It will also have access to a local skilled workforce, on-site engineering and project development expertise and R&D science institutes.

Based on scoping studies undertaken to date, the Plant is expected to have highly competitive operating costs.

Feasibility Studies and Technical Team

Extensive scoping studies and due diligence has been completed to date on the Plant site. Further feasibility studies will be completed by Carester, SENET (a DRA Global Group Company) and a local engineering firm, Prozap, together with support from Grupa Azoty PULAWY. The Carester team has extensive operating and advisory experience in rare earth separation at industrial scale, and will also provide ongoing technical support during construction and operation of the Plant. Mkango is also working closely with ANSTO to optimise feed specifications for the Plant.

Mkango will also be supported by its Chief Technical Advisor, Mike Vaisey, formerly Vice President, Research and Technology, for Lynas Corporation.Mr Vaisey has 25 years of international experience in the mining and chemical industries, in senior operational and technical development roles, with a track record of successful technology commercialisation.

Development of the Plant is expected to be underpinned by the sustainable supply of a purified mixed rare earth carbonate from Mkango's Songwe Hill project in Malawi. Mkango will also evaluate the potential to process third party feeds.

The feasibility studies for the Plant will run in parallel with those for the Songwe Hill rare earths project.

The Company will seek to maximise the renewable energy content and minimise the carbon impact of the developments in both Malawi and Poland, as part of the feasibility studies.

Environmental and Social Benefits

In addition to synergies with the existing operations, the Plant is expected to bring significant benefits to Poland and the EU, including additional jobs and potential for further downstream value-added develo

Spend some time over the weekend and go over this again ....all of it. Very enlightening. Imo

https://www.investegate.co.uk/mkango-resources-ltd--mka-/rns/mkango-to-create-rare-earths-hub-in-poland/202106070700109361A/

William Dawes, Chief Executive of Mkango stated: "Development of this Plant will underline Mkango's unique positioning in the rare earths sector. Our integrated "mine, refine, recycle" strategy, encompassing sustainably sourced light (NdPr) and heavy (Dy/Tb) rare earths from Malawi and rare earth magnet (NdFeB) recycling in the UK, via our interest in HyProMag, is now enhanced by the opportunity to create a rare earths separation and downstream hub in Poland, working with one of Europe's largest chemical and fertilizer companies.

"Rare earths are a vital component of magnets required in many technologies needed for the green energy transition. Therefore, their security of supply is becoming increasingly important to governments worldwide, especially in Europe and the US. We have carried out extensive due diligence on the site and believe the development of the Plant in Poland will enhance the sustainable supply of rare earths into Europe, as well as bringing significant benefits to the region, creating new jobs and potential, additional, downstream developments.

"We very much look forward to working with Grupa Azoty PULAWY and our partners worldwide to create value for all stakeholders and contribute to development of a more robust and sustainable rare earths supply chain. "

Andrzej Skwarek, Management Board Member of Grupa Azoty PULAWY stated: "We look forward to working together with Mkango on this exciting project, which complements the adjacent activities of Grupa Azoty PULAWY, benefiting from synergies in relation to reagents, by-products, utilities and infrastructure. As an industry leader in Poland, Grupa Azoty PULAWY welcomes this potential new development to the region and will continue to support Mkango as it progresses through the feasibility studies."

Jaroslaw Paczek, Mkango's Country Director for Poland stated: "This is a very exciting development for Poland at a time when Europe is focused on strengthening supply chains for critical materials and transitioning to a greener economy. The creation of a new European hub for rare earths at the heart of central Europe in Poland complements battery, electric vehicle and renewable energy developments in the region, with a site strategically located for European trade and transport routes and benefiting from plug and play access to reagents and utilities. I look forward to working with Mkango and Grupa Azoty PULAWY on this groundbreaking project for Poland and Europe. "

Hopefully will halt this rot

Trolls..over to you. Bound to discredit whatever?

I'd rather trust a Russian in New York than some of the R/souls posting on here...ffs

Just to re'cap for those that don't bother to research..try forcing yourselves, you might just learn something

April 2021
https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/final-results/202104301427202811X/

June 2021
https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/u.s.-approval-and-issuance-of-cdx-antibody-patent/202106021611456330A/

Last year i believr. But nothing has basically changed.. imo

All investors should recieve notification, no matter how many shares you hold. Unless they have not got a contact email address.

When i first read this i used it for my basic research snd NOT what i read on this bb.
My advice is this: If you believe the company is a scam and zProactive are backing up the lies then SELL. Otherwise i suggest the naysayers should 'button it' and shut the f/ up.

https://www.proactiveinvestors.co.uk/LON:HEMO/HemoGenyx-Pharmaceuticals/

Moaning about news is ridiculous, yes we need it and fast but moaning about the lack of it will not make the CEO hurry it through...how the f/ can he, FFS.